Humanwell Healthcare (Group) Co.,Ltd. (SHA: 600079)

China flag China · Delayed Price · Currency is CNY
23.48
+1.06 (4.73%)
Nov 20, 2024, 3:00 PM CST
-0.38%
Market Cap 37.77B
Revenue (ttm) 25.56B
Net Income (ttm) 1.96B
Shares Out 1.61B
EPS (ttm) 1.19
PE Ratio 19.71
Forward PE 16.21
Dividend 0.30 (1.34%)
Ex-Dividend Date Oct 11, 2024
Volume 29,106,808
Open 22.24
Previous Close 22.42
Day's Range 22.20 - 23.90
52-Week Range 15.68 - 27.36
Beta 0.84
Analysts n/a
Price Target n/a
Earnings Date Oct 28, 2024

About Humanwell Healthcare (Group) Co.,Ltd.

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia with artificial respiration; remifentanil hydrochloride for Injection for induction of general anesthesia; hydromorphone hydrochloride injection For patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injection for general anesthesia induction... [Read more]

Sector Healthcare
Founded 1993
Employees 17,676
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2023, Humanwell Healthcare (Group) Co.,Ltd.'s revenue was 24.52 billion, an increase of 9.79% compared to the previous year's 22.34 billion. Earnings were 2.13 billion, a decrease of -14.07%.

Financial Statements

News

There is no news available yet.